Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01219114
Recruitment Status :
(Inability to recruit patients within the specified time period. No patients have been enrolled in the study.)
The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.
Condition or disease
Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
several private and government tertiary hospitals
Diagnosis of cSSSI known or suspected to be due to gram-positive bacteria
Diagnosis of right-sided endocarditis with one or more positive culture for S. aureus within two days prior to initiation of medication
Prescribed daptomycin by patient's attending physician
Known allergic or serious adverse reaction to daptomycin
Patients with pneumonia
Patients with baseline CPK values >1000 U/L or 5x ULN